A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer

Conditions

• Gynecologic Cancer
• Gynecologic Tumor
• Head and Neck Cancer
• Head and Neck Tumor
• Melanoma
• Ovarian Cancer
• Thoracic Cancer
• Thoracic Tumor

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• IM@Home — BEHAVIORAL
  Participants in the IM@Home group will receive a 12-week virtual, synchronous, mind-body and fitness program. The Classes will be conducted via Zoom video conferencing platform. Patients will choose from a variety of weekly classes, occurring one to four times per week. An Integrative Medicine Service (IMS) clinical therapist (e.g., licensed dance therapist, certified yoga instructor, nurse specialist/physical trainer) with specific expertise in the oncology setting will lead each session. Activities range from more movement-based (fitness, yoga, dance therapy, or tai chi) to meditative-based classes (meditation, guided meditation, or music therapy). All clinicians will provide an overview of the session, 25 to 40 minutes of content, and five minutes for feedback and discussion. Each class lasts 30 to 45 minutes with optional audio or video participant participation and group chat.
• Enhanced usual care — BEHAVIORAL
  Patients in the enhanced usual care will receive usual care. In addition, once enrolling into the trial, they will be given a handout to encourage them to visit the MSK's multimedia page on the Integrative Medicine website to access pre-recorded, on-demand meditation audio or video recordings for meditation, guided imagery, and relaxation.

Study Details

The overarching long-term goal of the Integrative Medicine for Patient-reported Outcomes Values and Experience (IMPROVE) research program is to evaluate whether integrating a virtual mind-body programming, Integrative Medicine at Home (IM@Home), will improve patient perceived values, outcomes, and experiences as they undergo systemic cancer treatment such as chemotherapy, immunotherapy, radiotherapy, targeted agents, cytoreductive surgery.

Key Dates

Start date

Sep 20, 2021

Status verified

Oct 2025

Primary completion

Sep 20, 2026

Completion

Sep 20, 2026

Study Design

Enrollment

480 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Arms

• Experimental: IM@Home
  Participants with head and neck tumors, thoracic tumors, gynecological tumors, melanoma, breast cancer, or ovarian cancer
• Other: Enhanced usual care
  Participants with head and neck tumors, thoracic tumors, gynecological tumors, melanoma, breast cancer, or ovarian cancer

Primary Outcome Measure

Average Fatigue Severity from the Brief Fatigue Inventory (BFI) [ Time Frame: 12 weeks ]

Central Contacts

• Karolina Bryl, PhD
  646-608-8573
  [email protected]
• Michael Postow, MD
  646-888-4315
  [email protected]

Locations (7)

Find similar trials in Basking Ridge, NJ

Related Studies

• Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women
  Recruiting · M.D. Anderson Cancer Center · Miami, Florida
• Integrated Cancer Repository for Cancer Research
  Recruiting · University of Nebraska · Greenwood Village, Colorado
• A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
  PHASE1/PHASE2 · Recruiting · Merck Sharp & Dohme LLC · Aurora, Colorado
• Reflectance Confocal Microscopy of Oral Cancers in Vivo: a Preliminary Trial Comparing Intra-oral Imaging With Pathology
  Recruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey